Hemab Starts Phase 3 Trial for Glanzmann Disorder
The SOLARA trial will test sutacimig, an investigational once-weekly antibody, as prophylactic therapy for a rare inherited platelet disorder.
Updated on Nov. 10, 2026 in Biotech

Hemab Therapeutics has begun the SOLARA phase 3 trial of sutacimig in people with Glanzmann thrombasthenia, a serious inherited platelet function disorder. The open-label, single-arm study will enroll approximately 75 participants aged 12 to 70 years.
Why it matters
No prophylactic therapy for Glanzmann thrombasthenia is currently approved, leaving patients without a preventive option for bleeding. Phase 2 data supporting the trial design were presented at the ISTH 2026 Congress.
Phase 2 data showed a 62% reduction in high-intensity annualized treated bleed events among 34 participants, with three reporting Grade 2 thromboembolic events and no related Grade 3 or higher events. Whether these results will hold in the larger phase 3 population of about 75 people has not been established.
The players
Hemab Therapeutics
Hemab Therapeutics is a biotechnology company developing antibody-based therapies for rare bleeding disorders, and is the sponsor of the SOLARA trial.
International Society on Thrombosis and Haemostasis (ISTH)
The International Society on Thrombosis and Haemostasis is a global professional organization for researchers and clinicians in blood clotting and bleeding disorders, which hosted the 2026 Congress where the phase 2 data were presented.
The details
SOLARA is an open-label, single-arm, multicenter phase 3 trial testing sutacimig, a once-weekly subcutaneous bispecific antibody designed to help form stable clots at bleeding sites. Each participant serves as their own control across two consecutive periods, and eligibility requires at least four treated bleeding events in the prior 12 months.
Timeline
ISTH 2026 Congress: phase 2 data presented supporting the SOLARA design.
Fourth quarter 2026: first participants scheduled to enter the run-in period.
Development Pipeline
The SOLARA trial advances sutacimig from the phase 2 long-term extension, which treated 34 participants for a median of 6.9 months, into a larger phase 3 study. The move follows the pattern of rare-disease antibody programs that use within-patient controls to assess bleeding endpoints before broader approval.
Adults and adolescents with Glanzmann thrombasthenia who have had recurrent bleeding may gain access to a preventive option if SOLARA succeeds. Enrollment requires at least four treated bleeding events in the prior 12 months, so the trial is not open to people with fewer episodes.
The takeaway
A once-weekly preventive antibody could change how people with Glanzmann thrombasthenia manage recurrent bleeding, but the phase 3 results will determine whether early signals hold. Patients considering participation should discuss eligibility, including the four-bleed requirement, with their treating hematologist.
What happens next
First participants are scheduled to enter the SOLARA run-in period in the fourth quarter of 2026, and adolescent enrollment will be gated by data safety monitoring committee review.
Further reading
Explore more biotech developments in rare-disease therapeutics.
Source note: This article includes information reported by Pharmabiz.



